WASHINGTON (dpa-AFX) – New research suggests that some weight-loss drugs could raise the risk of serious eye problems that may cause vision loss.<\/p>\n
One previous study, published in JAMA, looked at data from nearly 1.5 million people. It found that people with diabetes taking medicines like semaglutide or tirzepatide had a higher risk of developing optic nerve disorders. This includes a rare but serious condition called non-arteritic anterior ischaemic optic neuropathy (NAION), also known as an ‚eye stroke.‘ <\/p>\n
A related research suggested that the chance of getting NAION from semaglutide was about 1 in 10,000. But the new study found it could be about 1 in 2,500 among type 2 diabetes patients taking semaglutide or tirzepatide.<\/p>\n
Another large study of 185,000 people linked these drugs, known as GLP-1 receptor agonists, to a higher risk of diabetic retinopathy, where blood vessels in the retina get damaged.<\/p>\n
Interestingly, patients on these drugs in both studies actually had fewer severe vision problems from diabetic retinopathy and needed fewer invasive eye treatments than those on other diabetes medicines.<\/p>\n
While the overall risk remains low, researchers recommend that all diabetes patients using these drugs whether or not they already have eye problems should get regular eye check-ups to catch any complications early.<\/p>\n
Copyright(c) 2025 RTTNews.com. All Rights Reserved<\/p>\n
Copyright RTT News\/dpa-AFX<\/p>\n","protected":false},"excerpt":{"rendered":"WASHINGTON (dpa-AFX) – New research suggests that some weight-loss drugs could raise the risk of serious eye problems…\n","protected":false},"author":2,"featured_media":4508,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[137],"tags":[29,42476,30,141,232,81075,95817,95818,42478,95819,95820,42676,95816],"class_list":{"0":"post-342235","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-gesundheit","8":"tag-deutschland","9":"tag-drugs","10":"tag-germany","11":"tag-gesundheit","12":"tag-health","13":"tag-loss","14":"tag-raise","15":"tag-rare","16":"tag-risk","17":"tag-stroke","18":"tag-studies","19":"tag-warn","20":"tag-weight"},"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@de\/115022990429752671","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/de\/wp-json\/wp\/v2\/posts\/342235","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/de\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/de\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/de\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/de\/wp-json\/wp\/v2\/comments?post=342235"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/de\/wp-json\/wp\/v2\/posts\/342235\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/de\/wp-json\/wp\/v2\/media\/4508"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/de\/wp-json\/wp\/v2\/media?parent=342235"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/de\/wp-json\/wp\/v2\/categories?post=342235"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/de\/wp-json\/wp\/v2\/tags?post=342235"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}